Integer Holdings Corporation has recently released its 10-K report, providing a detailed insight into its financial performance and operations. The company operates as a medical device contract development and manufacturing organization, serving various medical markets such as interventional cardiology, structural heart, peripheral vascular, neurovascular, and more. Integer Holdings Corporation is a strategic partner of choice for medical device customers, offering industry-leading engineering and manufacturing with a relentless commitment to quality, service, and innovation.
In the 10-K report, Integer Holdings Corporation discusses the impact of global events on its future results of operations and liquidity. The company highlights potential adverse effects from uncertainty surrounding macroeconomic and geopolitical factors, including inflationary pressure, changes in interest rates, disruptions in the commodities’ markets, and the introduction of tariffs or trade barriers. Integer Holdings Corporation emphasizes its ability to monitor economic conditions closely and take actions to align its cost structure with changes in demand.
The report also provides a sales outlook, indicating that in 2026, sales growth is expected to be impacted by lower sales related to three new products due to lower than anticipated market adoption. Additionally, the report details the issuance of $1.0 billion in aggregate principal amount of 1.875% Convertible Senior Notes due in 2030 and the exchange of $383.7 million in aggregate principal amount of outstanding 2.125% Convertible Senior Notes due in 2028 for an aggregate cash exchange consideration of $384.4 million in cash and 1,553,806 shares of common stock.
Furthermore, the 10-K report discusses the company's business acquisitions, including the acquisition of certain assets of Biocoat, VSi, Precision, and Pulse Technologies, Inc. These acquisitions are part of Integer Holdings Corporation's strategy to acquire additional technology or manufacturing capabilities to expand its product offering in key existing growth markets.
The report also covers the divestiture of Electrochem Solutions, Inc., a wholly-owned subsidiary of Integer Holdings Corporation, and its classification as discontinued operations. The company completed the sale of Electrochem, which focused on nonmedical applications for the energy, military, and environmental sectors, on October 31, 2024.
In terms of financial results, the report provides a comparison between 2025 and 2024. It highlights that income from continuing operations for 2025 was $102.8 million or $2.89 per diluted share, compared to $121.1 million or $3.40 per diluted share for 2024. The report details changes in sales, gross profit, operating expenses, interest expense, gains and losses on equity investments, other losses, and provisions for income taxes.
Today the company's shares have moved 0.59% to a price of $85.78. For more information, read the company's full 10-K submission here.
